<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011370</article-id><article-id pub-id-type="publisher-id">ACM-38503</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_55565395.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  sST2和NT-proBNP在射血分数保留心衰中的研究进展
  Research Progress of sST2 and NT-proBNP in Heart Failure with Preserved Ejection Fraction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>悦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>齐</surname><given-names>微</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>哲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夜</surname><given-names>雪敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>如雪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谷</surname><given-names>秀娟</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学医学院，陕西 延安</addr-line></aff><aff id="aff3"><addr-line>延安大学附属东关分院检验科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2451</fpage><lpage>2456</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    心力衰竭是多种心血管系统疾病发展终末期的共同结局。近年来随着生活方式改变和人口老龄化进程加快，射血分数保留的心力衰竭(heart failure with preserved ejection fraction, HFpEF)患病率及死亡率逐年上升，严重影响了人们的生活质量，故探寻与其诊断及预后相关的血清生物标志物有重要意义。本文主要就N末端脑钠肽前体(NT-proBNP)及可溶性生长刺激表达基因2蛋白(s-ST2)与HFpEF之间的关系做一综述，以期明确HFpEF的诊断，并为其治疗及预后评估提供参考。
    Heart failure is the common outcome of the end-stage development of a variety of cardiovascular diseases. In recent years, as lifestyle changes and the aging process of the population accelerate, the prevalence and mortality of heart failure with preserved ejection fraction (HFpEF) have increased year by year, which has seriously affected people’s quality of life, so explore Serum biomarkers related to its diagnosis and prognosis are of great significance. This article mainly reviews the relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and soluble growth-stimulating expression gene 2 protein (s-ST2) and HFpEF, in order to clarify the diagnosis of HFpEF and its treatment and prognosis evaluation provides reference. 
  
 
</p></abstract><kwd-group><kwd>可溶性ST2，N末端脑钠肽前体，射血分数保留的心力衰竭, Soluble ST2</kwd><kwd> N-Terminal Pro-Brain Natriuretic Peptide</kwd><kwd> Heart Failure with Preserved Ejection Fraction</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>心力衰竭是多种心血管系统疾病发展终末期的共同结局。近年来随着生活方式改变和人口老龄化进程加快，射血分数保留的心力衰竭(heart failure with preserved ejection fraction, HFpEF)患病率及死亡率逐年上升，严重影响了人们的生活质量，故探寻与其诊断及预后相关的血清生物标志物有重要意义。本文主要就N末端脑钠肽前体(NT-proBNP)及可溶性生长刺激表达基因2蛋白(s-ST2)与HFpEF之间的关系做一综述，以期明确HFpEF的诊断，并为其治疗及预后评估提供参考。</p></sec><sec id="s2"><title>关键词</title><p>可溶性ST2，N末端脑钠肽前体，射血分数保留的心力衰竭</p></sec><sec id="s3"><title>Research Progress of sST2 and NT-proBNP in Heart Failure with Preserved Ejection Fraction<sup> </sup></title><p>Yue Wang<sup>1</sup>, Wei Qi<sup>1</sup>, Zhe Wang<sup>1</sup>, Xuemin Ye<sup>1</sup>, Ruxue Bai<sup>1</sup>, Xiujuan Gu<sup>2*</sup></p><p><sup>1</sup>Yan’an University School of Medicine, Yan’an Shaanxi</p><p><sup>2</sup>Department of Laboratory Medicine, Dongguan Branch of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/4-1571631x5_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Oct. 29<sup>th</sup>, 2020; published: Nov. 5<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/4-1571631x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Heart failure is the common outcome of the end-stage development of a variety of cardiovascular diseases. In recent years, as lifestyle changes and the aging process of the population accelerate, the prevalence and mortality of heart failure with preserved ejection fraction (HFpEF) have increased year by year, which has seriously affected people’s quality of life, so explore Serum biomarkers related to its diagnosis and prognosis are of great significance. This article mainly reviews the relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and soluble growth-stimulating expression gene 2 protein (s-ST2) and HFpEF, in order to clarify the diagnosis of HFpEF and its treatment and prognosis evaluation provides reference.</p><p>Keywords:Soluble ST2, N-Terminal Pro-Brain Natriuretic Peptide, Heart Failure with Preserved Ejection Fraction</p><disp-formula id="hanspub.38503-formula32"><graphic xlink:href="//html.hanspub.org/file/4-1571631x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1571631x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1571631x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>2016年欧洲心脏病学会 [<xref ref-type="bibr" rid="hanspub.38503-ref1">1</xref>] (ESC)心力衰竭协会(HFA)修正了心力衰竭(HF)的分类，根据左室射血分数将HF分成3类：射血分数保留的心力衰竭(heart failure with preserved ejection fraction, HFpEF; LVEF ≥ 50%)、射血分数中间值的心力衰竭(heart failure with mid-range ejection fraction, HFmrEF; LVEF 40%~49%)及射血分数减低的心力衰竭(heart failure with reduced ejection fraction, HFrEF; LVEF &lt; 40%)。射血分数保留的心力衰竭(HFpEF)既往被称为舒张性心力衰竭，其是相对于收缩功能不全性心衰提出的。HFpEF [<xref ref-type="bibr" rid="hanspub.38503-ref2">2</xref>] 是由于心室舒张功能障碍和(或)心室肌顺应性降低僵硬度增高而导致左心室充盈受损、心脏搏出量减少而不能满足机体组织代谢需求，主要表现为运动耐力下降、呼吸困难和体液潴留，是一种多因素导致的复杂临床综合征。据统计 [<xref ref-type="bibr" rid="hanspub.38503-ref3">3</xref>]，HFpEF在全部心力衰竭中占比约为40%~71% (平均50%)，其主要危险因素包括：高龄、高血压、左心室肥厚、心肌梗死、瓣膜性心脏病、心房颤动、肥胖和糖尿病。研究显示 [<xref ref-type="bibr" rid="hanspub.38503-ref4">4</xref>]，HFpEF是由危险因素和基础共患疾病引起的全身、微血管内皮炎症、过度氧化应激和血管功能障碍，进而导致心肌细胞炎症、肥大和心肌纤维化。故探讨反映心血管系统压力负荷、炎症及心室肌纤维化的指标，对HFpEF早期发现和明确诊断有重要意义。</p></sec><sec id="s6"><title>2. sST2及其与HFpEF的关系</title><sec id="s6_1"><title>2.1. sST2的来源、生物学特性及其功能</title><p>1989年日本学者Tominaga等 [<xref ref-type="bibr" rid="hanspub.38503-ref5">5</xref>] 从BALB/c-3T3细胞(即小鼠成纤维细胞)中分离出一组生长特异性cDNAs，其中一个cDNA (被暂命名为ST2)编码的蛋白质序列与小鼠ILl-R系统的脱细胞部分高度相似，此蛋白即被称为ST2蛋白。2002年WEINBERG等 [<xref ref-type="bibr" rid="hanspub.38503-ref6">6</xref>] 发现ST2基因在心肌细胞发生机械应变时被显著激活，进而使ST2蛋白的表达异常上调。通过实验进一步验证：冠状动脉结扎组小鼠血清ST2水平较未结扎组瞬时升高(20.8 &#177; 4.4 vs 0.8 &#177; 0.8 ng/mL, P &lt; 0.05)，心肌梗死后1天，血清可溶性ST2水平升高，且ST2水平与射血分数呈负相关。2017年美国心脏病学会、美国心脏协会、美国心力衰竭学会对2013年的心衰管理指南进行了更新 [<xref ref-type="bibr" rid="hanspub.38503-ref7">7</xref>]，更新内容包括心衰生物标记部分、射血分数减低心衰(HFrEF)的新疗法、与HFpEF相关的重要共病的新数据以及预防心衰的新视点。指南 [<xref ref-type="bibr" rid="hanspub.38503-ref7">7</xref>] 指出：可溶性ST2与心室重塑和心肌纤维化相关，BNP和NT proBNP可用于心衰的诊断及其严重程度的判断。</p><p>sST2即可溶性生长刺激表达基因2蛋白，也被称为可溶性人基质裂解素2，是白细胞介素1受体家族的成员，其配体是细胞因子白细胞介素33 (IL-33)。ST2蛋白主要有两种异构体 [<xref ref-type="bibr" rid="hanspub.38503-ref8">8</xref>]：一种是可溶性形式的ST2或sST2，另一种是膜结合受体形式的ST2或ST2L。sST2可以捕获IL-33，进而影响IL-33/ST2L信号转导通路使心肌纤维化和心室重塑。细胞因子IL-33是sST2和ST2L的功能性配体，IL-33与ST2L结合对心血管系统产生有益作用，可以抑制心肌细胞肥大及心肌纤维化，从而起到保护心脏的作用。但sST2作为一种诱骗受体捕获白细胞介素33 [<xref ref-type="bibr" rid="hanspub.38503-ref9">9</xref>]，抑制其与ST2L的结合，阻止了IL-33对心脏的保护作用。</p></sec><sec id="s6_2"><title>2.2. sST2与HFpEF的关系</title><p>可溶性ST2与心室肥厚、纤维化及左心室重构密切相关 [<xref ref-type="bibr" rid="hanspub.38503-ref10">10</xref>]，其浓度升高&gt;35 ng/ml可预测为心衰预后不良。研究显示 [<xref ref-type="bibr" rid="hanspub.38503-ref11">11</xref>] 可溶性ST2水平与年龄、肾功能损害、体重指数、是否有心衰及心房颤动史无关，且对于NT-proBNP升高不明显的心衰也有很好地预测作用，对心衰患者病情的评估更准确。杨东慧等 [<xref ref-type="bibr" rid="hanspub.38503-ref12">12</xref>] 指出可溶性ST2对于HFpEF更有临床诊断价值。一项纳入了134例心力衰竭患者的研究 [<xref ref-type="bibr" rid="hanspub.38503-ref13">13</xref>] 显示，sST2与左室射血分数及收缩末期容积明显相关，即其与心脏结构之间存在相关性。可溶性ST2 [<xref ref-type="bibr" rid="hanspub.38503-ref14">14</xref>] 作为一种新型心力衰竭标志物，其参与心力衰竭之后心肌重构的病理生理过程，且在炎症反应、心肌纤维化和心脏氧化应激中的作用引起广泛关注。多项临床试验证明 [<xref ref-type="bibr" rid="hanspub.38503-ref15">15</xref>] sST2在多种心血管疾病发生的早期就有提示作用，且其水平对多种心血管疾病的预后有较高临床价值。sST2与心衰严重程度和不良预后显著相关，且对于急、慢性心衰患者的危险分层有一定的补充作用。由于sST2在机体发生炎症反应和免疫性疾病时水平升高 [<xref ref-type="bibr" rid="hanspub.38503-ref16">16</xref>]，因此联合检测NT-proBNP可以更准确的判断心衰的严重程度及预后情况。</p></sec></sec><sec id="s7"><title>3. NT-proBNP及其与HFpEF的关系</title><sec id="s7_1"><title>3.1. NT-proBNP的来源、生物学特性及其功能</title><p>美国国家临床生物化学研究院(NACB)的一个多学科专家小组 [<xref ref-type="bibr" rid="hanspub.38503-ref17">17</xref>] 将B型钠尿肽(BNP)、N末端pro BNP (NT-proBNP)纳入心血管疾病的危险因素中，并将其应用于心脏病和中风的一级预防。BNP是一种主要由心室肌细胞产生的多肽类激素 [<xref ref-type="bibr" rid="hanspub.38503-ref18">18</xref>]，最初由日本学者发现，并命名为脑钠肽。心肌细胞释放脑钠肽的主要触发因素是心肌细胞的伸展，当心室肌细胞受到的压力增大而发生主动或被动伸展就会促使BNP的产生和释放。但随后的研究表明 [<xref ref-type="bibr" rid="hanspub.38503-ref19">19</xref>]，其合成和分泌主要是受BNP基因表达水平的调控，当心室压力超负荷、容积扩张拉伸和心肌缺血时BNP基因大量激活，其被激活后产生pro-BNP (BNP前体或称BNP原)，pro-BNP是一种非活性多肽，其再经裂解酶作用生成等量的BNP和NT-proBNP。BNP是脑钠肽的一种活性形式 [<xref ref-type="bibr" rid="hanspub.38503-ref20">20</xref>]，半衰期短且性质相对不稳定，故更具有临床应用价值的是NT-proBNP，其半衰期长达1~2 h，在体内浓度24 h维持恒定，且检测不受时间、体位及日常活动的影响。人体内BNP和NT-proBNP的水平受年龄、体重指数、肾脏功能等多种因素的影响 [<xref ref-type="bibr" rid="hanspub.38503-ref21">21</xref>]，且由于二者代谢机制不同，在不同人群中二者的水平不完全一致，故不能仅依靠BNP或NT-proBNP的水平诊断HFpEF。所以在诊断HFpEF时不能依赖于单一指标，应该将多种指标联合检测、综合考虑，从而更科学准确地判断病情。</p></sec><sec id="s7_2"><title>3.2. NT-proBNP与HFpEF的关系</title><p>HFpEF患者约占心力衰竭患者总数的50% [<xref ref-type="bibr" rid="hanspub.38503-ref22">22</xref>]，其临床表现虽不及HFrEF严重，但预后与HFrEF相当，且更容易发生猝死。由于预期寿命延长、人口老龄化和心脏、非心脏性基础共患疾病的流行使得HFpEF的患病率呈现逐年上升的趋势。一项流行病学研究发现 [<xref ref-type="bibr" rid="hanspub.38503-ref23">23</xref>]：和HFrEF相比，HFpEF正以每年1%的速度增长。目前，HFpEF的病理机制尚未阐明，临床症状和体征缺乏特异性，临床医生的诊断存在很大难度，也缺乏有效的治疗策略。HFpEF患者 [<xref ref-type="bibr" rid="hanspub.38503-ref24">24</xref>] 的左心室没有明显的扩张，但会出现左室壁厚度增加和(或)左心房扩大，左心室的充盈和抽吸能力受损。2019ESC-HFA (欧洲心脏病学会心力衰竭协会)针对HFpEF的诊断提出了新的专家共识 [<xref ref-type="bibr" rid="hanspub.38503-ref25">25</xref>]，即四步诊断流程和HFA-PEFF评分。评估内容的第一步：心衰的症状和体征、心电图、合并症、危险因素、心脏超声心动图和心肺运动试验。第二步：采用HFA-PEFF评分，其是以超声心动图和利钠肽为基础评估内容，评分 ≥ 5分即可诊断为HFpEF。第三步：对于不能明确诊断的，需进行运动负荷超声心动图以及有创血流动力学检查。第四步：进行病因学诊断，包括心肌组织活检或基因检测等。该指南强调，对于HFpEF的诊断和治疗要注重基础疾病的作用，针对病因进行对应的治疗。</p><p>N末端脑钠肽前体蛋白是近年来很有前途的生物标志物。它已被用作 [<xref ref-type="bibr" rid="hanspub.38503-ref26">26</xref>] 心脏病患者、普通人群和重症监护室患者的风险分层工具。在一项纳入了576名非选择重症监护室患者的大规模研究中 [<xref ref-type="bibr" rid="hanspub.38503-ref27">27</xref>] 发现，在对患者的年龄、肾功能和炎症等混杂因素进行调整后，NT-proBNP可以独立预测心脏病病人的重症监护室死亡率。王云的一项研究 [<xref ref-type="bibr" rid="hanspub.38503-ref28">28</xref>] 纳入了60例心力衰竭患者，选择同期健康体检者60例作为对照组，并将心衰组按照美国纽约心脏病学会心功能分级的标准分为四组，结果发现：心衰各组的NT-proBNP水平均高于健康对照组，且随着心功能分级的增加其水平逐渐升高，说明NT-proBNP水平与心衰的严重程度存在一定的相关性。其次，NT-proBNP在鉴别心源性和非心源性呼吸困难方面发挥了很大作用，从而对临床的诊断和治疗起到了指导作用。杨国平 [<xref ref-type="bibr" rid="hanspub.38503-ref29">29</xref>] 纳入了因急性呼吸困难入院和在住院期间出现呼吸困难症状的101例患者，综合所有患者的病史、临床症状、体征、超声心动图、胸片、心电图以及各项化验检查结果将其分为心脏病引起的呼吸困难组(49例)和肺脏疾病引起的呼吸困难组(52例)，同时检测所有入选者的血浆NT-proBNP水平。结果发现：心脏病引起的呼吸困难患者的NT-proBNP水平明显高于肺脏疾病引起的呼吸困难者。</p></sec></sec><sec id="s8"><title>4. NT-proBNP联合sST2与HFpEF的关系</title><p>NT-proBNP和sST2作为新型心力衰竭标志物，都与心血管系统压力负荷、炎症及心室肌纤维化的程度相关。闫福堂等 [<xref ref-type="bibr" rid="hanspub.38503-ref30">30</xref>] 纳入了216例心衰患者，按照纽约心功能分级标准分为心功能I级(62例)、II级(58例)、III级(54例)和IV级组(42例)，同时将心功能正常的80例作为健康对照组，检测血清中的sST2和血浆中的NT-proBNP水平。结果发现病例组的sST2和NT-proBNP水平显著高于健康对照组，差异具有统计学意义(P &lt; 0.05)，且随着心功能分级升高，二者的水平也逐渐升高。sST2和NT-proBNP可以作为心力衰竭诊断的新型生物标志物，二者联合检测优于单独检测，有助于提高对心力衰竭的诊断价值。崔圆等 [<xref ref-type="bibr" rid="hanspub.38503-ref31">31</xref>] 选择了70例慢性心衰患者作为病例组，将同期诊断为单纯性高血压和心律失常的30例患者作为对照组，检测所有纳入者的GDF-15、sST2和BNP，得出三者的水平与心功能分级密切相关，且均可反映病情严重程度；通过ROC曲线分析得出：在判断慢性心衰患者心功能分级时，BNP有较高的特异度和灵敏度。</p></sec><sec id="s9"><title>5. 小结及展望</title><p>综上所述，sST2和NT-proBNP在心衰的早期诊断、鉴别诊断、严重程度的分级和治疗方面有重要的临床价值，同时血清sST2可作为心衰患者预后的生物标志物。但是，sST2在判断心力衰竭病情严重程度时的截值尚无确切定论，因此，有待于多中心大样本研究，进一步明确其与心衰严重程度分级的关系，以指导心衰的早期诊断及精准治疗。最后，临床研究显示：sST2和NT-proBNP的浓度还与高血压、肺动脉高压、急性创伤等疾病相关。因此，如何将二者与其他实验室指标相结合用于心衰相关性疾病的鉴别、诊断及预后将成为研究热点。</p></sec><sec id="s10"><title>文章引用</title><p>王 悦,齐 微,王 哲,夜雪敏,白如雪,谷秀娟. sST2和NT-proBNP在射血分数保留心衰中的研究进展Research Progress of sST2 and NT-proBNP in Heart Failure with Preserved Ejection Fraction[J]. 临床医学进展, 2020, 10(11): 2451-2456. https://doi.org/10.12677/ACM.2020.1011370</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38503-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Oeing, C.U., Tschöpe, C. and Pieske, B. (2016) The New Esc Guidelines for Acute and Chronic Heart Failure 2016. Herz, 41, 655-663. &lt;br&gt;https://doi.org/10.1007/s00059-016-4496-3</mixed-citation></ref><ref id="hanspub.38503-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">魏安华, 李娟. 《中国心力衰竭诊断和治疗指南2018》药物更新透视[J]. 医药导报, 2019, 38(5): 539-543.</mixed-citation></ref><ref id="hanspub.38503-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bui, A.L., Horwich, T.B. and Fonarow, G.C. (2011) Epidemiology and Risk Profile of Heart Failure. Nature Reviews Cardiology, 8, 30-41. &lt;br&gt;https://doi.org/10.1038/nrcardio.2010.165</mixed-citation></ref><ref id="hanspub.38503-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Oikonomou, E., Vogiatzi, G., Tsalamandris, S., et al. (2018) Non-Natriuretic Peptide Biomarkers in Heart Failure with Preserved and Reduced Ejection Fraction. Biomarkers in Medicine, 12, 783-797.  
&lt;br&gt;https://doi.org/10.2217/bmm-2017-0376</mixed-citation></ref><ref id="hanspub.38503-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tominaga, S. (1989) A Putative Protein of a Growth Specific Cdna From Balb/c-3t3 Cells Is Highly Similar to the Extracellular Portion of Mouse Interleukin 1 Receptor. FEBS Letters, 258, 301-304.  
&lt;br&gt;https://doi.org/10.1016/0014-5793(89)81679-5</mixed-citation></ref><ref id="hanspub.38503-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., et al. (2002) Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation, 106, 2961-2966.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.0000038705.69871.D9</mixed-citation></ref><ref id="hanspub.38503-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yancy, C.W., Jessup, M., Bozkurt, B., et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136, e137-e161.</mixed-citation></ref><ref id="hanspub.38503-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">曾艳, 谭华清, 唐湘宇, 等. 可溶性ST2与心血管疾病关系的研究进展[J]. 实用心脑肺血管病杂志, 2019, 27(5): 112-116.</mixed-citation></ref><ref id="hanspub.38503-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Demyanets, S., Kaun, C., Pentz, R., et al. (2013) Components of the Interleukin-33/ST2 System Are Differentially Expressed and Regulated in Human Cardiac Cells and in Cells of the Cardiac Vasculature. Journal of Molecular and Cellular Cardiology, 60, 16-26. &lt;br&gt;https://doi.org/10.1016/j.yjmcc.2013.03.020</mixed-citation></ref><ref id="hanspub.38503-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mccarthy, C. and Januzzi, J. (2018) Soluble St2 in Heart Failure. Heart Failure Clinics, 14, 41-48.  
&lt;br&gt;https://doi.org/10.1016/j.hfc.2017.08.005</mixed-citation></ref><ref id="hanspub.38503-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Mueller, T., Rehman, S.U. and Januzzi, J.L. (2008) Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure. Journal of the American College of Cardiology, 52, 1458-1465.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2008.07.042</mixed-citation></ref><ref id="hanspub.38503-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">杨东慧. 血浆sST2与不同类型心力衰竭的关系[J]. 中国分子心脏病学杂志, 2017, 17(6): 2321-2324.</mixed-citation></ref><ref id="hanspub.38503-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Shah, R.V., Januzzi, J.L., Picard, M.H., et al. (2009) Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients with Acute Dyspnea. Circulation Heart Failure, 2, 311-319. &lt;br&gt;https://doi.org/10.1161/CIRCHEARTFAILURE.108.833707</mixed-citation></ref><ref id="hanspub.38503-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Liu, H., Sun, R.-R., Li, X.-C., et al. (2014) Biomarkers and Heart Disease. European Review for Medical and Pharmacological Sciences, 18, 2927-2935.</mixed-citation></ref><ref id="hanspub.38503-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">王同霞, 陈章荣. 可溶性ST2与心力衰竭患者预后的评价[J]. 心血管病学进展, 2020, 41(5): 495-498.</mixed-citation></ref><ref id="hanspub.38503-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">徐亚妹, 葛均波. 新型心衰标志物sST2的生物学特征和临床意义[J]. 中华检验医学杂志, 2015(7): 498-501.</mixed-citation></ref><ref id="hanspub.38503-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Myers, G.L., Christenson, R., et al. (2009) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease. Clinical Chemistry, 55, 84-378.  
&lt;br&gt;https://doi.org/10.1373/clinchem.2008.115899</mixed-citation></ref><ref id="hanspub.38503-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Xia, W., Huang, Y., Chen, Y., et al. (2011) Acute Myocardial Ischemia Directly Modulates the Expression of Brain Natriuretic Peptide at the Transcriptional and Translational Levels via Inflammatory Cytokines. European Journal of Pharmacology, 670, 7-12. &lt;br&gt;https://doi.org/10.1016/j.ejphar.2011.09.012</mixed-citation></ref><ref id="hanspub.38503-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">陈华, 周懿忆, 戴屹东. NT-proBNP的临床应用进展[J]. 标记免疫分析与临床, 2015, 22(1): 69-72.</mixed-citation></ref><ref id="hanspub.38503-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">韩肖肖, 杨蒙, 邵淑梅, 谷秀娟. NT-proBNP在急性冠状动脉综合征中的研究进展[J]. 医学理论与实践, 2018, 31(4): 491-493, 502.</mixed-citation></ref><ref id="hanspub.38503-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">李立健, 饶绍奇, 田镭钢, 梁岩. BNP或NT-proBNP对冠心病的临床意义[J]. 海南医学, 2017, 28(5): 784-787.</mixed-citation></ref><ref id="hanspub.38503-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">金雅丽, 张倩辉, 郭艺芳. 左心室射血分数保留的心力衰竭研究现状[J]. 心血管病学进展, 2010, 31(1): 96-98.</mixed-citation></ref><ref id="hanspub.38503-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Oktay, A.A., Rich, J.D. and Shah, S.J. (2013) The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 10, 401-410. &lt;br&gt;https://doi.org/10.1007/s11897-013-0155-7</mixed-citation></ref><ref id="hanspub.38503-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37, 2129-2200.</mixed-citation></ref><ref id="hanspub.38503-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">徐俊波, 黄刚, 蔡琳, 等. 2019ESC-HFA射血分数保留性心力衰竭诊断共识的解读[J]. 心血管病学进展, 2019, 40(9): 1193-1195, 1211.</mixed-citation></ref><ref id="hanspub.38503-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Januzzi, J.L., Morss, A., Tung, R., et al. (2006) Natriuretic Peptide Testing for the Evaluation of Critically Ill Patients with Shock in the Intensive Care Unit: A Prospective Cohort Study. Critical Care, 10, R37.  
&lt;br&gt;https://doi.org/10.1186/cc4839</mixed-citation></ref><ref id="hanspub.38503-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Wang, F., Pan, W., Pan, S., et al. (2011) Usefulness of N-Terminal Pro-Brain Natriuretic Peptide and C-Reactive Protein to Predict ICU Mortality in Unselected Medical ICU Patients: A Prospective, Observational Study. Critical Care (London, England), 15, R42. &lt;br&gt;https://doi.org/10.1186/cc10004</mixed-citation></ref><ref id="hanspub.38503-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">王云. NT-proBNP在心力衰竭诊断及治疗效果评估中的检测价值[J]. 心血管病防治知识(学术版), 2019, 9(17): 41-42.</mixed-citation></ref><ref id="hanspub.38503-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">杨国平. 急性呼吸困难患者检测NT-proBNP的护理体会[J]. 安徽卫生职业技术学院学报, 2014(3): 84-85.</mixed-citation></ref><ref id="hanspub.38503-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">闫福堂, 苏宝凤, 詹颉, 等. 血清可溶性ST2与血BNP在心力衰竭患者中的相关性研究[J]. 现代检验医学杂志, 2015, 30(6): 78-79, 83.</mixed-citation></ref><ref id="hanspub.38503-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">崔圆, 金凤表, 孙瓅贤, 等. 血清GDF-15、sST2、BNP检测在慢性心力衰竭患者心功能评估中的价值[J]. 山东医药, 2016, 56(17): 1-4.</mixed-citation></ref></ref-list></back></article>